Verastem (VSTM) EBT Margin (2018 - 2026)

Verastem (VSTM) posted quarterly EBT Margin of 238.1% for Q1 2026, down 2.36% quarter-over-quarter from 232.6% in Q4 2025.

Analysis

Verastem (VSTM) EBT Margin (2018 - 2026) Analysis & Trends

Verastem's EBT Margin history runs 8 years deep, the most recent figure standing at 238.1% for Q1 2026.

In Q1 2026, EBT Margin changed N/A year-over-year to 238.1%; the TTM figure through Mar 2026 stood at 370.01% (changed N/A YoY), while the FY2025 annual figure was 677.59%, up 62693.0% from the prior year.
EBT Margin for Q1 2026 stood at 238.1%, down from 232.6% in the prior quarter.
The five-year high for EBT Margin was 184.32% in Q2 2024, with the low at 2524.61% in Q2 2025.
The 4-year median for EBT Margin is 315.97% (2026), against an average of 705.95%.
The sharpest annual moves came in 2022 and 2025: EBT Margin jumped 130151 bps in 2022, then plunged 234029 bps in 2025.
Verastem's EBT Margin stood at 662.21% in 2022, then jumped by 72 bps to 184.32% in 2024, then fell by 26 bps to 232.6% in 2025, then decreased by 2 bps to 238.1% in 2026.
Business Quant data shows VSTM's EBT Margin at 238.1% in Q1 2026, 232.6% in Q4 2025, and 393.84% in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	35.61%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	35.78%
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-528.97%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	18.33%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	13.77%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	12.09%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-2.67%
10	Verastem	814.94 Mn	678.59 Mn	36.32 Mn	-84.48%

Historic Data

Download Data